Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | SERPINE1 | P05121 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31693952 | 1.00 | MAPT (0.56) | MAPTSMN1; SMN2SERPINE1MAPK1PKM | |
| SCHEMBL7978483 | 0.81 | SMN1; SMN2 (0.68) | MAPTSMN1; SMN2SERPINE1ALDH1A1LMNA | |
| SCHEMBL7981185 | 0.81 | SMN1; SMN2 (0.68) | MAPTSMN1; SMN2SERPINE1ALDH1A1LMNA | |
| SCHEMBL10452284 | 0.81 | MAPT (0.57) | MAPTSMN1; SMN2SERPINE1TDP1ALDH1A1 | |
| SCHEMBL10452286 | 0.81 | MAPT (0.57) | MAPTSMN1; SMN2SERPINE1TDP1ALDH1A1 | |
| SCHEMBL16796890 | 0.80 | AR (0.46) | MAPTSMN1; SMN2ALDH1A1L3MBTL1LMNA | |
| SCHEMBL31694062 | 0.78 | MAPT (0.36) | MAPTSMN1; SMN2SERPINE1MAPK1PKM | |
| SCHEMBL2064392 | 0.78 | TDP1 (0.63) | MAPTSMN1; SMN2SERPINE1TDP1ALDH1A1 | |
| SCHEMBL27692447 | 0.78 | TDP1 (0.63) | MAPTSMN1; SMN2SERPINE1TDP1ALDH1A1 | |
| SCHEMBL8140544 | 0.77 | CCR1 (0.47) | MAPTSMN1; SMN2SERPINE1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1201820-C | Compositions containing benzimidazolones and progestogens | WYETH CORP (US) | 2005-05-18 | — | — | CN | disclosed |
| US-6794373-B2 | ADMINISTERING TO A FEMALE OF CHILD BEARING AGE OVER A PERIOD OF 28 CONSECUTIVE DAYS A FIRST PHASE OF FROM 18 TO 21 DAILY DOSAGE UNITS OF A PROGESTATIONAL AGENT, AND A SECOND PHASE OF FROM 1 TO 7 DAILY DOSAGE UNITS OF AN ANTIPROGESTIN AGENT | WYETH | 2004-09-21 | — | — | US | disclosed |
| US-20020151531-A1 | Contraceptive methods using benzimidazolones | LIGAND PHARMACEUTICALS INCORPORATED | 2002-10-17 | — | — | US | disclosed |
| US-20020115853-A1 | Benzimidazolones and analogues | WYETH | 2002-08-22 | — | — | US | disclosed |
| US-6423699-B1 | CONTRACEPTIVES | AMERICAN HOME PRODUCTS CORPORATION | 2002-07-23 | — | — | US | disclosed |
| CN-1349411-A | Compositions containing benzimidazolones and progestogens | AMERICAN HOME PROD (US) | 2002-05-15 | — | — | CN | disclosed |
| US-6380235-B1 | USEFUL AS PROGESTERONE RECEPTOR AGONISTS AND ANTAGONISTS, USED FOR CONTRACEPTION, IN THERAPY OF FIBROIDS, ENDOMETRIOSIS, BREAST, UTERINE, OVARIAN AND PROSTATE CANCER, AND POST MENOPAUSAL HORMONE REPLACEMENT THERAPY | AMERICAN HOME PRODUCTS CORPORATION | 2002-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151531-A1 | Contraceptive methods using benzimidazolones | PGR, GNRHR, NR4A1 | MAPT 4875/4885SMN1; SMN2 4622/4885SERPINE1 2964/4885 |
| US-20020115853-A1 | Benzimidazolones and analogues | PGR, NR5A1, NR3C2 | MAPT 4870/4885SMN1; SMN2 4423/4885SERPINE1 3906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.